The Economist For more than two years Novo Nordisk had the entirety of the market for weight-loss drugs to itself. This year, Eli Lilly will pull ahead
For more than two years Novo Nordisk had the entirety of the market for weight-loss drugs to itself. This year, Eli Lilly will pull ahead